Vacci-Test Corporation Launches VACCI-TEST(TM)-Tetanus in Europe
Vacci-Test Corporation (“Vacci-Test”) is pleased to announce that its French subsidiary, Vacci-Test Europe (“VTE”), has launched its first human diagnostic test, VACCI-TEST(TM) -Tetanus in France and Germany. The product is being distributed by Groupe ServioBio, one of Europe’s largest distributors of point-of-care diagnostic tests to hospitals and emergency clinics.
VACCI-TEST(TM) -Tetanus is a rapid, sensitive, lateral flow diagnostic assay that determines the immune status of an individual by detecting the presence of circulating antibodies.
Mr. Bernard Boyer, Managing Director of VTE, stated “We are confident that our new product will become the assay of choice as a rapid, reliable point-of-care Tetanus test and will avoid the need and expense of unnecessary revaccination. The need for rapid results has changed the way diagnostic tests are being designed and used and Vacci-Test has developed products that are more sensitive and quantitative to meet this need.”
Mr. William Hogan, Vice Chairman of Vacci-Test, stated “The successful commercial launch of our first product, VACCI-TEST(TM) -Tetanus represents a major milestone in the company’s short operating history.”
Vacci-Test is a privately held Canadian company that specializes in second generation magnetic lateral flow tests for the rapid and precise detection and measurement of immune status and infection in animals and humans, and pathogens in food. A key element in Vacci-Test’s product pipeline is a series of tests for the burgeoning food safety market for the measurement of pathogens such as E.coli O157:H7 associated with the human food chain.
This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its private filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts: Vacci-Test Corporation William J. Hogan Vice Chairman (403) 269-9424 Vacci-Test Corporation The Honourable Charlie Mayer Director of Corporate Development (403) 269-9424 (403) 263-6357 (FAX) Vacci-Test Corporation Suite 1005, 550 - 11th Avenue S.W. Calgary, Alberta, Canada T2R 1M7 Email: email@example.com Website: www.vaccitest.com
SOURCE: Vacci-Test Corporation